Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India
| Autor: | Brindha Thangaraj, Venkatraman Pitchaikannu, Prabhu Ramamoorthy, Janakiraman Thangarasu, Praveen Kumar Marimuthu, Manigandan Chandrasekaran, Vivek Sundaram, Govindaraj Ganesan, Raguram Shree Vaishnavi, Sasipriya Ponniah, Gunasekaran Kannupaiyan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Respiratory distress business.industry Viral pneumonia medicine.medical_treatment Hematology Oxygenation medicine.disease Anti-inflammatory therapy Radiation therapy Low dose radiotherapy Pneumonia Cytokine Oncology Internal medicine Immunomodulatory therapy medicine Original Article COVID-19 therapy Radiology Nuclear Medicine and imaging COVID-19 pneumonia business Cause of death |
| Zdroj: | Radiotherapy and Oncology |
| ISSN: | 0167-8140 |
| Popis: | Background and purpose The main cause of death in COVID-19 pneumonia is acute respiratory distress syndrome which is preceded by massive cytokine release. Low-dose radiation therapy (LDRT) has anti-inflammatory and immunomodulatory effects that can interfere with the inflammatory cascade, reducing the severity of associated cytokine release. Material & methods 25 patients with RT-PCR proven COVID-19 pneumonia were enrolled between November 2020 and May 2021. All patients had SpO2 24/min and SpO2/FiO2 ratio (SF ratio) of >89 but |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect